A previously healthy 22-month-old girl of Asian heritage presented with a 10-day history of high fever and a 3-day history of nonpurulent conjunctivitis, erythema and swelling of her left upper arm and right side of her neck, and reddened, swollen palms. She had emigrated from South Korea 6 weeks before her admission to hospital. Her immunizations, including BCG (bacille Calmette-Guérin) vaccination given at 9 months of age, were up to date.
On physical examination, the girl was irritable, and her temperature was 39.8°C. She had conjunctivitis and reddened lips, and a tender lymph node 2.5 × 1.5 cm in size was felt on the right side of her neck. She had mild erythema of her palms and a faint maculopapular rash on her chest. She also had marked erythema, induration and small areas of vesiculation on her left upper arm ( Fig. 1 Kawasaki disease was diagnosed, and intravenous gamma globulin therapy (2 g/kg) and high-dose ASA therapy (100 mg/kg daily) were started. The patient became afebrile during the gamma globulin infusion, and her clinical signs resolved over the next 24 hours. An echocardiogram showed ectasia of the right coronary artery. She was discharged home with a prescription of 40 mg of ASA daily; a follow-up echocardiogram done 4 weeks after discharge appeared normal.
Kawasaki disease is an acute systemic vasculitis that predominantly affects preschool-aged children. The disease has an incidence as high as 1 per 1000 children less than 5 years of age, it affects boys somewhat more often than girls, and it exhibits seasonal peaks in winter and spring.
1 The cause is unknown, but epidemiologic features suggest that the mechanism involves an immune response to a precipitating infection in genetically predisposed people. The diagnostic criteria for Kawasaki disease are listed in Box 1.
BCG vaccine is a live vaccine prepared from strains of Mycobacterium bovis and administered as a single intracutaneous injection. Although not protective against infection with Mycobacterium tuberculosis, the vaccine is relatively effective in preventing meningeal and miliary tuberculosis (TB) in children. The World Health Organization recommends BCG vaccination soon after birth in infants living in TB-endemic areas; the vaccine is currently used in more than 100 countries. In Canada, BCG vaccine is given selectively only to people at high risk of TB infection (infants living in First Nations or other communities that have a high incidence of TB, health care workers repeatedly exposed to patients with untreated or drug-resistant TB, and travellers planning extended stays in highly endemic areas).
In children who have received BCG vaccine, reactions of erythema, induration and ulcerations may occur at the site of inoculation with the development of Kawasaki disease. Reactions can also occur at the site of M. tuberculosis antigen skin tests. In the case described here, although only • Oral changes (dry, cracked lips, strawberry tongue)
• Extremity changes (erythema and edema of palms and soles)
• Cervical lymphadenopathy (> 1.5 cm, usually firm and tender) *Atypical Kawasaki disease, especially in young infants, may be diagnosed in patients with fewer than 4 criteria if coronary artery changes are present on echocardiography.
BCG vaccination was recalled and documented to have been given at the site of vesiculation, the pattern of vesiculation suggests possible reaction to a prior multiple-puncture skin test for M. tuberculosis. In Japan, where Kawasaki disease and BCG vaccination are both more common than in North America, 121 (43%) of 281 children who had Kawasaki disease within 3 years after BCG vaccination had cutaneous reactions at the inoculation site. 2 This observation led to this clinical feature being incorporated into the diagnostic guidelines suggested by the Japan Research Committee on Kawasaki Disease. Because BCG vaccination is uncommon in North America, clinicians are relatively unfamiliar with this clinical finding. The explanation for the reactions to BCG vaccine and tuberculin skin tests in children with Kawasaki disease is unclear, but studies support the hypothesis that there is molecular mimicry between specific mycobacterial and human proteins and that the activated immune system in cases of Kawasaki disease may be propagated by these antigens. The CMA is committed to providing leadership for physicians and promoting the highest standard of health and health care for Canadians. To strengthen the Association and be truly representative of all Canadian physicians, the CMA needs to hear from members interested in serving in elected positions and on appointed committees and advisory groups.
The CMA structure comprises both governing bodies and advisory bodies either elected by General Council or appointed by the CMA Board of Directors. The Board of Directors -elected by General Council -has divisional, affiliate, resident and student representation, is responsible for the overall operation of the CMA and reports to General Council on issues of governance. CMA councils and committees advise the Board of Directors and make recommendations on specific issues of concern to physicians and the public. Five core councils and committees consist of either divisional or regional representation, while other statutory and special committees and task forces consist of individuals with interest and expertise in subject-specific fields. Positions on one or more of these committees may become available in the coming year.
For further information on how you can get involved, please contact: By getting involved, you will have an opportunity to make a difference.
Paula Wilson
We hope to hear from you!
